Equities Analysts Offer Predictions for MIRM FY2027 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Investment analysts at Leerink Partnrs increased their FY2027 earnings per share (EPS) estimates for Mirum Pharmaceuticals in a report issued on Tuesday, November 4th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of $2.45 for the year, up from their prior forecast of $2.22. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share.

A number of other research firms also recently weighed in on MIRM. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Wednesday, October 8th. Raymond James Financial reiterated a “strong-buy” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, August 7th. JPMorgan Chase & Co. upped their target price on shares of Mirum Pharmaceuticals from $53.00 to $77.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Citizens Jmp raised their price target on shares of Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock a “market outperform” rating in a research note on Wednesday. Finally, Wall Street Zen raised Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, September 26th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Mirum Pharmaceuticals has an average rating of “Buy” and an average price target of $83.50.

Mirum Pharmaceuticals Stock Performance

MIRM opened at $68.11 on Thursday. The stock’s 50 day simple moving average is $72.95 and its 200-day simple moving average is $58.94. The company has a current ratio of 3.31, a quick ratio of 2.97 and a debt-to-equity ratio of 1.06. The stock has a market cap of $3.50 billion, a PE ratio of -79.20 and a beta of 0.75. Mirum Pharmaceuticals has a 1 year low of $36.88 and a 1 year high of $78.54.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The firm had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. During the same quarter in the prior year, the firm posted ($0.30) EPS. The company’s revenue for the quarter was up 47.1% on a year-over-year basis. Mirum Pharmaceuticals has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. CWM LLC grew its holdings in shares of Mirum Pharmaceuticals by 259.4% during the first quarter. CWM LLC now owns 593 shares of the company’s stock worth $27,000 after purchasing an additional 428 shares during the last quarter. MCF Advisors LLC lifted its position in Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after buying an additional 185 shares in the last quarter. Comerica Bank grew its holdings in Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after acquiring an additional 278 shares during the last quarter. Quarry LP acquired a new stake in Mirum Pharmaceuticals in the 1st quarter valued at about $56,000. Finally, Osaic Holdings Inc. increased its position in Mirum Pharmaceuticals by 46.5% in the 2nd quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock valued at $56,000 after acquiring an additional 351 shares in the last quarter.

Insider Activity at Mirum Pharmaceuticals

In other news, CFO Eric Bjerkholt sold 9,578 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $76.01, for a total value of $728,023.78. Following the completion of the transaction, the chief financial officer owned 39,945 shares in the company, valued at approximately $3,036,219.45. The trade was a 19.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Christopher Peetz sold 40,000 shares of the stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $62.00, for a total value of $2,480,000.00. Following the sale, the chief executive officer owned 138,641 shares in the company, valued at approximately $8,595,742. This trade represents a 22.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 66,578 shares of company stock valued at $4,472,824 in the last ninety days. Insiders own 14.36% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.